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Abstract
The proportion of patients defined as obese continues to grow in many westernized nations, particularly the United
States (USA). This trend has shifted the perioperative management of obese patients into the realm of routine care.
As obese patients present for all types of procedures, it is crucial for anesthesiologists, surgeons, internists, and
perioperative health care providers alike to have a firm understanding of their altered multi-organ physiology in
order to safely prepare the obese patient for an operation. A careful preoperative evaluation may also serve to
identify risk factors for postoperative adverse events. Subsequently, preoperative measures may be implemented to
mitigate these complications. In this manuscript we address the major considerations for the preoperative
evaluation of the severely obese patient.
Keywords: Obesity, Morbid obesity, Preoperative evaluation, Metabolic syndrome, Obstructive sleep apnea (OSA),
Bariatric, Body mass index, Insulin resistance
Introduction
“Thou seest I have more flesh than another man, and
therefore more frailty” W. Shakespeare (1564–1616),
Henry IV.
A condition known since antiquity, obesity has ‘grown’
from being the exception to a global public health chal-
lenge. A recent study reveals that between 1980 and
2013 the worldwide rates of overweight and obesity have
increased by 28 % in adults and 47 % in children. As of
2013, 2.1 billion are overweight and obese compared to
857 million in 1980. The United States is home to ap-
proximately 13 % of the world’s 671 million obese indi-
viduals [1]. The comorbidities associated with excess
weight result in a health burden that has a significant
economic impact [2].
Obesity is associated with conditions such as type 2
diabetes (T2DM), chronic kidney disease [3, 4], depression
[5], stroke [6] and coronary artery disease (CAD) [7].
These comorbidities, in addition to the type and invasive-
ness of the surgical procedure, are correlated with the in-
cidence and severity of postoperative complications [8, 9].
Excess weight is also associated with conditions that in
and of themselves increase the likelihood of needing sur-
gery and anesthesia: malignancies – notably, cervical,
endometrial, colorectal and gallbladder cancer [9]; osteo-
arthritis [10]; back pain [11]; stress incontinence [12] and
gallstones [13]. These conditions are a result of both
physiologic changes as well as inflammatory changes asso-
ciated with obesity.
In this manuscript, we aim to review the major obesity-
related co-morbidities and their impact on the preoperative
evaluation. Wherever data and/or expert opinion exist, we
provide guidance for perioperative management.
Review
Definition of obesity
The diagnosis of obesity is often based on body mass
index (BMI) calculated as weight in kilograms divided by
height in meters, squared. A BMI of 18.5 to 24.9 is consid-
ered normal, a BMI of 25–29.9 overweight and a BMI > 30
is considered obese. Obesity is further categorized into
Class I (BMI 30 – 34.9), Class II (BMI 35 – 39.9) and Class
III (BMI > 40) [14]. BMI is a global measure of body mass
encompassing both adipose tissue and lean mass. It ac-
counts for neither the proportion of each tissue nor the re-
gional distribution of adipose tissue, factors which can
have important implications for the clinical assessment of
patients. Independent of total weight, excess adiposity in
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the central area (visceral or intra-abdominal) is associated
with higher insulin resistance and risk of atherosclerotic
heart disease than a more peripheral distribution of fat
(gluteofemoral) [15, 16]. Consequently, indirect mea-
sures of central fat distribution, such as waist circumfer-
ence or waist-to-hip ratio (WHR), may be better markers
of obesity-related comorbidities such as CAD [7] and dys-
lipidemia [17].
Major changes associated with obesity
Inflammatory changes
Beyond its role in energy balance and the mechanical
load it imposes, adipose tissue impacts our bodies
through its endocrine properties. Excess weight results
when calories consumed exceed calories spent. The posi-
tive energy balance eventually leads to adipose tissue
hypertrophy, macrophage recruitment and to complex
adaptive changes in the adipocytes, their supporting tis-
sue, blood supply and immunological milieu. Over time,
adipocyte cell death and chronic tissue hypoxia occur as
the supply of nutrients and oxygen trails behind the de-
mands of the hypertrophic cells [18]. Among the obes-
ity-induced changes in adipose tissue activity is the
altered secretion of cell-signaling proteins known as
adipokines and the increased production of inflamma-
tory markers such as TNF-α and IL-6 by resident mac-
rophages [19, 20]. These mediators interact with the
sympathetic nervous system, the renin-angiotensin-
aldosterone system and individual organs -such as the
pancreas and liver- to effect the alterations in physi-
ology that accompany obesity [19, 21].
Metabolic syndrome
The chronic low-grade state of inflammation and im-
mune system activation that typifies obesity promotes
insulin resistance and the development of T2DM [22].
The metabolic syndrome is a group of conditions more
likely to occur together than randomly alone and increase
the risk of cardiovascular disease and T2DM. A recent
definition includes: elevated waist circumference (value
determined by individual populations) plus any two of the
following: elevated triglycerides (≥150 mg/dl), reduced
HDL-C (≤40 mg/dl in males, ≤50 mg/dl in females),
hypertension (systolic ≥ 130 and/or diastolic ≥ 85 mmHg)
and elevated fasting glucose (≥100 mg/dl) [23].
Physiologic changes
Cardiovascular
Changes in the cardiac system occur as a consequence
of the cardiovascular adaptation to excess body mass
and increased metabolic demands [24]. Approximately
31 % of individuals with extreme obesity, particularly if
long-standing, will develop structural and functional
changes that lead to obesity cardiomyopathy [25, 26].
Excess body mass requires an increase in intravascular
blood volume as well as an increase in cardiac output
(mostly from an increase in stroke volume). Over time,
the increase in stroke volume leads to an increase in left
ventricular load, dilation and compensatory left ventricu-
lar hypertrophy, a known precursor of heart failure [27].
Mechanical impairment also results from structural remod-
eling driven by prolonged exposure to factors that exert dir-
ect cardiotoxic effects (e.g. insulin resistance, steatosis,
neurohumoral over-activation) as well as the repeated cy-
cles of nocturnal hypoxia and hypercarbia associated with
intermittent airway obstruction characteristic of obstructive
sleep apnea. These eventually culminate in pulmonary
hypertension and biventricular dysfunction [28, 29].
Coronary artery disease
Risk factors for coronary artery disease (CAD) in pa-
tients with obesity include: T2DM, hypertension, dyslip-
idemia, heightened inflammation, and a prothrombotic
state. In a meta-analysis of 19,388 bariatric surgery pa-
tients, 7 % had a history of CAD [8]. Unfortunately,
symptoms associated with coronary ischemia, such as
dyspnea on exertion and chest pain, occur commonly in
obese patients and can be nonspecific [30].
The American Association of Clinical Endocrinolo-
gists, the Obesity Society, and the American Society of
Metabolic and Bariatric Surgery (AACE-TOS-ASMBS)
and the American College of Cardiologists and the
American Heart Association (ACC-AHA) have both
published guidelines for the perioperative evaluation of
the bariatric patient [31]. A preoperative electrocardio-
gram (ECG) should be obtained if cardiac disease is sus-
pected (i.e. patient has a risk factor for CAD or has
known stable cardiovascular disease). Obtaining a rou-
tine ECG in all-comers can lead to unnecessary tests
prompted by false positive results. In a study of bariatric
surgery patients, 62 % had ECG abnormalities which,
when evaluated by a cardiologist, did not constitute a
contraindication to bariatric surgery [32]. Signs of right
ventricular hypertrophy (right axis deviation, right bun-
dle branch block) on ECG may indicate pulmonary
hypertension, a significant risk factor for postoperative
complications [33]. A new left bundle branch block may
signal occult CAD. Both findings should prompt add-
itional investigation.
The need for further cardiac evaluation depends on an
in-depth analysis of the patient’s risk factors, cardiac risk
associated with the planned procedure and the patient’s
functional status. Older studies reported cardiac complica-
tions in 1 % to 1.4 % of patients undergoing open bariatric
surgical procedures [34]. More recently, less invasive pro-
cedures such as laparoscopic Roux-en-Y gastric bypass
and laparoscopic gastric banding have resulted in a lower
risk of cardiac complications (<0.5 %) [35]. This
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underscores the pivotal role of procedural risk factors - in
addition to patient risk factors - in assessing cardiac risk.
The Revised Cardiac Risk Index [36] and the American
College of Surgeons NSQIP Risk Calculator (access at:
http://www.surgicalriskcalculator.com) [37] are validated
tools to help estimate perioperative risk. Guidelines pub-
lished by the ACC-AHA [38] stipulate no further cardiac
testing if the risk of a major adverse cardiac event (MACE)
is < 1 %. If the MACE risk is ≥ 1 %, functional status
should be ascertained.
Functional status can be inferred from an individual’s
ability to perform activities of daily living. The ability to
perform > 4 metabolic equivalents (METS) of activity is
associated with a low risk of perioperative cardiac events
[39]. Patients undergoing bariatric surgery with a func-
tional capacity of < 4.5 METs as measured by exercise
testing had a 16.7 % complication rate (defined as death,
unstable angina, myocardial infarction, venous thrombo-
embolism (VTE), renal failure, or stroke). In contrast,
the complication rate in patients with a functional cap-
acity > 4.5 METs was 2.8 % [40]. Importantly, the assess-
ment of functional status is often difficult because of
limited mobility in patients with severe obesity [30]. For
the patient whose functional capacity is < 4 METS and
whose risk of MACE is high (≥1 %), stress testing repre-
sents a useful modality to determine ischemic potential.
Potential challenges include a patient’s inability to exercise,
lack of equipment to support excess weight, and inability
to obtain high-quality echocardiographic images due to
body habitus. If decreased cardiac function is uncovered,
cardiomyopathy secondary to obesity, diabetes, or long-
standing ischemia ought to be considered. Cardiomyop-
athy predisposes to heart failure, which entails higher risks
of operative mortality and hospital readmission [41].
Hypertension
Hypertension, traditionally defined as a systolic blood
pressure ≥ 140 mmHg or a diastolic blood pressure of ≥
90 mmHg [42], is an independent risk factor for the de-
velopment of CAD, stroke and structural end-organ in-
jury [43]. A direct relationship between excess weight
and elevated blood pressure has been demonstrated in
several population-based studies [44–46].
The etiology of hypertension in the setting of obesity
and the metabolic syndrome is multifactorial, resulting
from the interaction between genetic factors, insulin re-
sistance, sodium retention, activation of the sympathetic
nervous system as well as the activation of the renin-
angiotensin-aldosterone axis. No consensus currently ex-
ists on the optimal antihypertensive drug regimen in the
obese. However, angiotensin-converting-enzyme (ACE)
inhibitors and angiotensin receptor blockers (ARBs) are
favored by some investigators because of their ability to
increase insulin sensitivity, thus diminishing the risk of
diabetes mellitus [47]. To enhance its effectiveness,
treatment of obesity-related hypertension must include
emphasis on weight management through dietary and
behavioral modifications.
Arrhythmias
Arrhythmias in the obese may be precipitated by hypox-
emia, left atrial and ventricular enlargement, electrolyte
disturbances from diuretic therapy, increase in plasma
catecholamines and hypercarbia. A robust association
between obesity and atrial fibrillation (AF) [48] was
demonstrated in a cardiothoracic study where patients
with a BMI > 40 had a 2.3 fold increased risk of postop-
erative AF compared to a 1.2 fold increased risk in those
with a BMI between 25 and 30 [49]. Despite this associ-
ation, it is unclear whether AF confers a greater risk of
adverse perioperative cardiac events. Guidelines pub-
lished by the ACC/AHA note that “a paucity of studies
that address surgical risk conferred by arrhythmias limits
the ability to provide specific recommendations” [38].
However, a retrospective administrative database study
of 38,047 patients showed that a prior admission for AF
was associated with a higher perioperative mortality rate
than CAD [50]. Preoperative evaluation of the patient
with a history of AF involves an assessment of rate and/
or rhythm control as well as a review of medications,
particularly anticoagulants [38]. Patients with AF can be
managed with either heart rate control or conversion to
normal sinus rhythm as both AF and normal sinus
rhythm have comparable rates of mortality and stroke in
this population [51]. Current guidelines recommend a
target heart rate of less than 80 beats per minute, though
a “lenient” rate-control strategy (resting heart rate < 110
beats per minute) may be considered in asymptomatic
patients with preserved LV function [52].
The CHA2DS2-VASc score (Table 1) should be used
for risk stratification of thromboembolic risk in patients
with AF [52]. Patients with a CHA2DS2-VASc score
greater than 2 should receive anticoagulation therapy.
Perioperatively, the decision of whether or not to con-
tinue anticoagulation and the appropriate regimen for
each patient should balance the risk of bleeding with the
risk of stroke if therapy is discontinued.
Respiratory
Obesity’s impact on respiratory function (Table 2) is in-
versely related to BMI, with significant impairment ob-
served once BMI exceeds 45 [53]. Consistent with
restrictive physiology, the pattern of distribution of excess
weight - central vs. peripheral - is more consequential
than BMI per se. For further discussion, the reader is re-
ferred to the BMC Anesthesiology article by Fernandez-
Bustamante et al. [54].
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Obstructive sleep apnea
Magnetic resonance imaging studies confirm that
pharyngeal structures (from the nasopharynx to the lar-
yngopharynx) increase in size with deposition of adipose
tissue [55]. Additionally, King et al. have documented a
reduction in airway caliber (increase in airway resistance)
with increasing weight [56]. These changes in pharyngeal
shape are associated with impairment of pharyngeal dila-
tor activity and an increased risk of airway collapse [57].
Although obstruction may occur at any point in the phar-
ynx, it is most frequently observed in either the retropala-
tal and/or the retroglossal regions [57].
Obstructive sleep apnea (OSA), a sleep-related breath-
ing disorder, is estimated to affect between 40 % and
90 % of obese individuals [57]. It is characterized by
periodic reduction or cessation of breathing due to nar-
rowing of the upper airways during sleep. Factors linking
obesity and OSA include anatomical imbalance from ex-
cess upper airway fat deposition, changes in upper air-
way muscle tone [58, 59], as well as alterations in the
control of ventilation [60]. Furthermore, OSA itself leads
to changes that contribute to the development of obesity:
decreased energy level, motivation, sleep fragmentation
etc. While the majority of individuals with severe obesity
are able to maintain eucapnia, a significant minority will
develop obesity hypoventilation syndrome (OHS), charac-
terized by alveolar hypoventilation (PaCO2 > 45 mmHg)
unexplained by other disorders [61, 62].
OSA can negatively affect perioperative outcome. The
Longitudinal Assessment of Bariatric Surgery (LABS)
study found that a history of OSA was significantly asso-
ciated with a composite endpoint of death, VTE, reinter-
vention, or failure to be discharged by 30 days after
surgery [63]. However, preoperative intervention may re-
verse this impact. Weingarten et al. did not find an asso-
ciation between OSA and postoperative respiratory,
cardiac, or surgical complications in affected patients
who were treated preoperatively with continuous posi-
tive airway pressure (CPAP) or bi-level positive airway
pressure (biPAP) for several weeks to months and were
monitored with pulse oximetry postoperatively [64].
As OSA is often undiagnosed, routine polysomnogra-
phy (PSG) for patients undergoing bariatric surgery has
been recommended [32, 65]. Though this test is the gold
standard for diagnosis, it is costly and time-consuming.
Furthermore, whether or not routine screening improves
safety and outcomes is debatable. A study of 1,058,710 pa-
tients undergoing elective orthopedic, abdominal, prostate,
and cardiovascular surgery found that sleep-disordered
breathing (SDB) was not associated with a clinically sig-
nificant increase in in-hospital mortality, length of stay or
total charges [66]. However, patients with SDB were more
likely to have cardiopulmonary complications such as AF,
respiratory failure, emergency intubation, as well as non-
invasive and mechanical ventilation.
A protocol for the evaluation of patients at risk for
OSA is an integral component of the preoperative as-
sessment of the obese [67]. Questions regarding snoring,
apneic episodes, frequent arousals during sleep, morning
headaches, and daytime somnolence should be explored.
The physical examination should include an evaluation of
the airway, neck circumference, tongue size and volume,
and nasopharyngeal characteristics. Despite varying sensi-
tivities and specificities, tools such as the STOP-Bang
questionnaire [68], Epsworth Sleepness Scale [69] or the
Berlin questionnaire [70] can facilitate the OSA screening
process. The STOP-Bang questionnaire (Table 3) [68], de-
veloped specifically for use in surgical patients, has been
validated in patients with a BMI > 30 [71]. In the obese, a
STOP-Bang score of ≥ 3 has a sensitivity of 90.5 % for de-
tecting OSA with a positive predictive value of 84.8 %. A
score of ≥ 5 is associated with a sensitivity of 53 % and a
specificity of 70.2 % for predicting moderate/severe OSA
(defined as an apnea-hypopnea index [AHI] >15) and a
sensitivity of 68.8 % and a specificity of 68.7 % for predict-
ing severe OSA (AHI > 30).
Table 1 CHA2DS2-VASc Score
Parameter Score
Congestive Heart Failure 1
Hypertension 1
Age ≥ 75 2
Age 65-74 1
Diabetes Mellitus 1
Stroke/Transient ischemic attack 2
Vascular disease (prior MI, peripheral arterial disease, aortic plaque) 1
Sex category (Female) 1
Table 2 Respiratory changes with obesity [119–124]
Parameter Obesity-Related Change
Work of breathing (WOB) Increased
Functional residual capacity (FRC) Decreased
Expiratory reserve volume (ERV) Decreased
Total lung capacity (TLC) Unchanged, though
decreased in severe obesity
Vital capacity (VC) Decreased
Forced expiratory volume in 1 s (FEV1) Unchanged, though
decreased in severe obesity
Forced vital capacity (FVC) Unchanged, though
decreased in severe obesity
FEV1/FVC Unchanged, though
decreased in severe obesity
Diffusing capacity of the lung
for carbon monoxide (DLCO)
Unchanged in simple obesity
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When clinical screening identifies a patient as poten-
tially having OSA, the decision whether to manage him
clinically preoperatively or to obtain sleep studies and
initiate OSA treatment prior to surgery should take into
account the severity of OSA (based on clinical indicators
or sleep study results), the invasiveness of the planned
procedure, and the estimated postoperative narcotic
requirement [67]. A recent Cochrane review found no
evidence that CPAP reduces postoperative mortality;
however, it may offer benefit in preventing pneumonia,
reducing atelectasis, and lowering the risk of reintuba-
tion [72]. While studying the incidence of serious post-
operative complications (e.g. cardiac events) in OSA
patients, Gupta et al. found a lower incidence in those
treated with preoperative CPAP than in the untreated
group [73]. In a recent trial, OSA patients treated with
CPAP for a 12-week period showed a reduction in mean
arterial pressure whereas those who received only noctur-
nal supplemental oxygen or education did not [74]. Des-
pite insufficient data to conclusively establish the benefits
of pre- and postoperative CPAP, the American Society of
Anesthesiologists (ASA) [67] recommends considering the
perioperative initiation of CPAP, particularly if OSA is
severe. In patients already treated with CPAP or non-
invasive positive pressure ventilation (NIPPV), this treat-
ment should be continued into the postoperative period
unless contraindicated [67].
Asthma
A meta-analysis involving 333,102 subjects demonstrated
that obese individuals (BMI > 30) were nearly twice as
likely to have asthma as individuals with a BMI < 25 [75].
Predisposing factors included: decreased airway caliber
due to decreased lung volumes; altered airway smooth
muscle contractility leading to increased airway respon-
siveness and the chronic, low-grade inflammatory state
associated with obesity [76]. Obese patients are more likely
to have severe asthma and to respond poorly to inhaled
corticosteroids and long-acting beta agonists. Weight loss
is associated with improved asthma control [76].
Pulmonary hypertension
Obese patients have multiple risk factors for developing
pulmonary hypertension (PH) such as OSA, OHS, left
heart dysfunction, and chronic pulmonary thromboembol-
ism. Patients with PH are at increased risk for morbidity
and mortality with anesthesia and surgery. Kaw et al. re-
ported that 26 % of patients with PH (defined as a mean
pulmonary artery pressure of > 25 mmHg) experienced
postoperative morbidity or mortality as compared to a
2.6 % complication rate in patients without PH. Compared
to controls, patients with PH had a significantly higher
risk of developing congestive heart failure, respiratory fail-
ure, hemodynamic instability and sepsis. Factors associ-
ated with increased risk of complications included poor
functional status (New York Heart Association functional
class ≥ II), history of pulmonary embolism, OSA, and sur-
gical complexity [77]. Other risk factors included longer
time under anesthesia (>3 h) and intraoperative vasopres-
sor use.
Patients with PH should have a preoperative ECG, chest
radiograph, and an echocardiogram to assess ventricular
and valvular structure and function. Right-sided heart
catheterization is indicated for patients with pulmonary
arterial hypertension [78]. The data should be reviewed
for characterization of pulmonary hemodynamics (pul-
monary artery pressures, pulmonary vascular resistance),
cardiac output (looking for signs of right heart failure),
and response to vasodilator therapy [79]. Other guidelines
for perioperative management include continuing baseline
pulmonary vascular targeted therapy (i.e. phosphodiester-
ase type 5 inhibitors, soluble guanylate cyclase stimulators,
endothelin receptor antagonists, and prostanoids) [38].
Preoperative evaluation by a PH specialist can be invalu-




Adults with a BMI ≥ 40 are 7 times more likely to have
diabetes compared to normal weight individuals [80].
Improved preoperative glycemic control has been associ-
ated with decreased postoperative complications and im-
proved diabetes remission rates after bariatric surgery.
One retrospective, single center study of 468 patients
undergoing bariatric surgery showed that 26.5 % of pa-
tients with a Hgb A1c of <6.5 % had a postoperative
complication as compared to 36.4 % of patients with a
Hgb A1c of > 8 %. Patients with poorly controlled dia-
betes were more likely to have wound infections, acute
Table 3 STOP-BANG questionnaire
Snoring Do you Snore Loudly?
Tired Do you often feel Tired, Fatigued,
or Sleepy during the daytime?
Observed Has anyone Observed you Stop Breathing
or Choking/Gasping during your sleep?
Pressure Do you have or are you being treated
for High Blood Pressure?
Body Mass Index BMI > 35 kg/m2
Age Age > 50 years
Neck Circumference Shirt collar > 17 in/43 cm for males
Shirt collar > 16 in/41 cm for females
Gender Gender =male
The STOP-Bang questionnaire is a screening tool for OSA. In obese patients, a
score of 0–3 indicates a low risk of OSA, a score of 4–5, an intermediate risk of
OSA, and a score of 6–8, a high risk of OSA [71]. Adapted
from http://www.stopbang.ca/screen.php
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renal failure, and postoperative leaks. [81]. The AACE-
TOS-ASMBS recommends a target Hgb A1c value of
6.5 % to 7.0 % or less perioperatively, though more lib-
eral targets (Hgb A1c of 7 %-8 %) can be considered in
patients with extensive co-morbid conditions or difficult
to control diabetes [31].
Gastrointestinal
Liver disease
In parallel with the rising obesity rate, non-alcoholic
fatty liver disease (NAFLD) is becoming the most com-
mon chronic liver disease worldwide [82]. Histologic
changes begin with fatty infiltration (steatosis) and can
Table 4 Major obesity-related conditions and pertinent studies
Organ System Major issues Pertinent studies
Cardiovascular • ECG if cardiac disease is suspected
Coronary artery disease • Use validated tools to estimate risk of perioperative MACE
• If risk of MACE≥ 1 % and functional status is poor, consider stress testing
Pulmonary hypertension • Consider right ventricular hypertrophy, pulmonary hypertension if ECG shows
right axis deviation, right bundle branch block
• Echocardiogram to assess right and left ventricular function & morphology,
valvular morphology, estimate pulmonary artery pressure
• Right heart catherization
Congestive heart failure • Chest radiograph
• Echocardiogram
Respiratory
Dyspnea • Chest radiograph
Asthma • Pulmonary function testing not recommended for routine screening
Obstructive sleep apnea • Screen for OSA with history, physical exam, validated screening questionnaire
• Consider polysomnogram
• Consider initiating CPAP/biPAP preoperatively
Hypoventilation syndrome • Arterial blood gas
Gastrointestinal
GERD • Upper endoscopy
• 24-h pH monitoring
• Esophageal manometry
• Barium swallow (upper gastrointestinal series)
NAFLD • Liver function tests (LFTs)
• Triglyceride level
• Liver ultrasound if LFTs elevated or symptomatic biliary disease
H. Pylori • Stool antigen test
• Urea breath test
• Endoscopy – rapid urease test
Endocrine
Diabetes mellitus • Measure Hgb A1c
• Optimize glycemic control
Hematologic
VTE • Assess VTE risk: degree of obesity, age, history of previous DVT or hypercoagulable state,
history of malignancy, immobility
Psychologic • Psychosocial-behavioral evaluation
Depression / anxiety • Identify patients at risk for suicide
Binge eating disorder
Nutritional • Iron studies, B12, folate, 25-hydroxyvitamin D
• Electrolytes, calcium, magnesium, phosphate levels
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progress to non-alcoholic steatohepatitis (NASH) once in-
flammatory changes are superimposed. In 15-20 % of pa-
tients, NASH can progress to cirrhosis [83], placing the
affected individual at higher risk of developing hepatocellu-
lar cancer, portal hypertension, ascites and liver failure [84].
In patients scheduled for weight-loss surgery the prevalence
of NAFLD and NASH has been estimated to be as high as
91 % and 37 %, respectively [85, 86]. Risk factors for meta-
bolic syndrome (abdominal obesity, insulin resistance) are
also risk factors for NAFLD and NASH [84, 87].
There are currently no serological biomarkers for
NAFLD, a commonly asymptomatic condition. NAFLD
should be suspected in individuals with metabolic syn-
drome with or without elevated liver function tests [88].
An elevated triglyceride level may identify obese patients
with liver disease. In 160 patients undergoing bariatric
surgery, a value >150 mg/dl was associated with a 3.4
fold greater risk of developing NASH. Alanine amino-
transferase (ALT) levels > 45 U/l were also associated with
NASH. On the other hand, elevated levels of HDL-C de-
creased the likelihood of NASH [89]. The diagnosis of
NAFLD is usually confirmed by imaging studies, most
commonly liver ultrasonography. Hernaez et al. showed in
a meta-analysis that this diagnostic tool had a sensitivity
of 84.8 % and specificity of 93.6 % for detecting steatosis
affecting greater than or equal to 20-30 % of hepatocytes
[90]. Liver biopsy is the gold standard for definitive diag-
nosis and staging of NAFLD and NASH [91].
NAFLD is not a benign entity. In 229 patients with
biopsy-proved NAFLD who were followed for a mean of
26.4 years, Ekstedt et al. observed an increase in mortal-
ity from cardiovascular and liver-related causes. Notably,
advanced fibrosis increased mortality with a hazard ratio
of 3.3 (95 % confidence interval 2.27- 4.76) [92]. Though
no pharmacologic regimen has been shown to halt pro-
gression of liver injury, early diagnosis and intervention
with lifestyle modification (e.g. increase in exercise,
change in diet), weight reduction and, potentially, par-
ticipation in clinical treatment trials may help reverse or
mitigate hepatic damage [93]. Although NAFLD affects
the expression and activity of hepatic enzymes involved
in drug metabolism [94], no recommendations currently
exist regarding alterations in anesthetic drug dosing in
patients with steatosis.
Gastroesophageal reflux disease
The prevalence of gastroesophageal reflux disease
(GERD) in the USA is reported to range between 18.1 %
and 27.8 % [95]. Although gastric emptying is normal in
otherwise healthy obese patients [96, 97], mechanical
and hormonal changes place obese individuals at higher
risk of GERD [98]. Frequent or severe GERD symptoms
increase the risk of Barrett’s esophagus [99] and esopha-
geal adenocarcinoma [100].
Infection with Helicobacter pylori (H. pylori) is a risk
factor for gastroduodenal ulcer disease, gastric cancer
and the development of marginal ulcers after gastric by-
pass surgery [101]. In 611 bariatric surgery patients,
23.7 % had H. pylori infection on preoperative endos-
copy with biopsy [102]. Proponents of routine preopera-
tive H. pylori testing and treatment argue that treatment
may decrease postoperative dyspeptic symptoms as well
as lower the risk of developing marginal ulcers and gas-
tric cancer [103]. However, routine screening prior to
bariatric surgery is not recommended given the paucity
of large, controlled trials examining the impact of H. pyl-
ori on postoperative outcomes [31].
Hematologic
Venous thromboembolism
In addition to the immobilization and venous stasis that
characterize the immediate perioperative period, the
obesity-related state of chronic inflammation [104] and im-
paired fibrinolysis [105] place the high BMI patient at an
increased risk for postoperative thromboembolic events, a
major cause of mortality following bariatric surgery. Com-
pared to a laparoscopic procedure, an open surgical pro-
cedure increases the risk of venous thromboembolism
(VTE) 4.5 fold [35]. In the LABS-1 study, 0.4 % of 4610 pa-
tients undergoing bariatric surgery developed VTE [63].
Among 73,921 patients from the Bariatric Outcomes Longi-
tudinal Database, 0.42 % developed VTE within 90 days of
surgery [35]. Furthermore, 73 % of VTE occurred after dis-
charge, with a median interval to VTE event of 14 days.
The mortality rate among patients who developed VTE was
25 %. Risk factors for postoperative VTE include increased
age, high BMI, male gender, and history of prior VTE.
The American College of Chest Physicians (ACCP)
considers obesity to be a high risk factor for VTE
[106]. Their guidelines for the prevention of VTE rec-
ommend chemoprophylaxis with either low dose
unfractionated heparin (LDUH) or low molecular weight
heparin (LMWH) in addition to mechanical prophylaxis
with elastic stockings or intermittent pneumatic compres-
sion. Additionally, the AACE-TOS-ASMBS encourages
early ambulation in the postoperative period [31]. Fonda-
parinux, low dose aspirin, or mechanical prophylaxis is
recommended for patients in whom LDUH or LMWH is
contraindicated due to heparin allergy or a history of
heparin-induced thrombocytopenia [106].
Most venous thromboembolic events occur after discharge
[35]. Raftopoulos et al. found that 66 % of VTE occurred
after cessation of thromboprophylaxis, but continuation of
chemoprophylaxis for 10 days post-discharge decreased the
risk of VTE in bariatric surgery patients [107]. Accordingly,
the AACE-TOS-ASMBS recommends continuing chemo-
prophylaxis after hospital discharge in high-risk patients (e.g.
those with history of DVT) [31].
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Inferior vena cava (IVC) filters have been used to pre-
vent VTE in high-risk obese patients. Indications for
placement include BMI > 50, history of VTE or venous
stasis, and history of hypercoagulable state [108]. Al-
though Birkmeyer et al. showed that prophylactic IVC
filter placement reduced the rates of postoperative VTE,
serious complications, or death/permanent disability
[109], the AACP does not recommend IVC filter place-
ment for primary VTE prevention [106].
Obesity-associated alterations to drug volume of distri-
bution and absorption imply that increased doses of
LDUH/LMWH may be needed to provide optimum
VTE prophylaxis. However, a lack of well-designed and
controlled trials precludes specific dosing recommenda-
tions. Nevertheless, there are recommendations for
therapeutic doses of LMWH. Enoxaparin dosing should
be based on total body weight up to a weight of 144 kg
[110]. Dalteparin can be dosed based on total body
weight up to a weight of 190 kg. In addition, twice daily
dosing is recommended because subtherapeutic anti-
factor Xa levels are more common with once daily dos-
ing. Monitoring of coagulation in the obese patient can
be achieved by measuring anti-factor Xa levels 4 h after
a dose.
Nutrition
Despite excess caloric intake, several nutritional
deficiencies have been associated with obesity [111]. Po-
tential contributors include inadequate intake of
nutrient-rich food, altered metabolism and bioavailabil-
ity of micronutrients and coexisting conditions such as
secondary hyperparathyroidism. During the pre-
bariatric surgery assessment of 267 outpatients with a
BMI > 35, Lefebvre et al. noticed that many were defi-
cient in 25-hydroxyvitamin D (67.9 %), magnesium
(35.4 %), phosphate (21.6 %), iron (18.8 %) and 16.9 %
had a low concentration of vitamin A [112]. Micronu-
trient deficiencies can have important physiologic im-
plications as evidenced by the association between low
levels of vitamin D and a higher risk of hypertension,
diabetes and cardiovascular diseases [113]. As the post-
operative period is generally characterized by changes
in food intake and absorption, it is important to ad-
dress these deficiencies prior to surgery in order to
prevent them from worsening afterwards.
Psychological changes
Obesity is associated with approximately a 25 % increase
in mood and anxiety disorders [114]. Data from the
National Epidemiologic Survey on Alcohol and Related
Conditions (NESARC), a psychiatric epidemiology study
of over 40,000 American adults, showed that BMI was
significantly associated with most mood and anxiety dis-
orders including depression, mania, panic disorder,
social phobia, and personality disorders. Furthermore,
there was a 3 to 5 % increased risk of mood and anxiety
disorders with every unit increase in BMI [115].
Several causative factors account for the link between
obesity and mood disorders. Commonly used atypical anti-
psychotics, mood stabilizers, and antidepressants often
cause some degree of weight gain. Depression is associated
with an increase in cortisol levels which is associated with
visceral weight gain. Sleep disturbance can result in imbal-
ances in leptin and ghrelin, hormones that mediate appe-
tite and satiety. Depression and obesity are both associated
with a low grade state of inflammation as well as a decrease
in dopamine activity [116]. Obese individuals also encoun-
ter negative societal attitudes resulting in social withdrawal
and alienation. One study reported a 12 % prevalence of
self-perceived discrimination based on weight, which is
comparable to the prevalence of other forms of discrimin-
ation such as age and race. Furthermore, as BMI increases
so does the perception of bias and discrimination [117].
The presence of mental disorders may complicate
post-surgical care. Patients may not have the cognitive
capacity to discern the risks and benefits of surgery and
may lack the motivation to comply with needed postop-
erative regimens. Because psychopathology may nega-
tively impact postoperative outcomes, many centers for
bariatric surgery require preoperative psychological con-
sultation to ascertain a patient’s mental fitness for under-
going weight loss surgery.
Other considerations
It is important to keep in mind that obesity is not a single
entity but a heterogeneous condition as diverse as cancer:
it has many causative factors and affects multiple organ
systems resulting in myriad medical and psychological co-
morbidities. As such, an all-inclusive medical care plan –
including the preoperative preparation – should have a
balanced or team-based approach. Comprehensive bariat-
ric surgery programs consist of nurses, nutritionists, inter-
nists, psychologists, social workers, physicians and other
consultants who work together to ensure the best out-
comes at all stages of management. Such an approach is
appropriate in the care of the medically complex obese pa-
tient presenting for non-bariatric surgery. Improving a pa-
tient’s physical condition through a preoperative exercise
program, optimization of nutrition and cessation of to-
bacco and alcohol consumption (“prehabilitation”) can en-
hance the patient’s functional capacity and, potentially,
facilitate post-surgical recovery [118]. Furthermore, se-
verely obese patients should be cared for in high-volume
facilities with the specialized expertise, personnel and
equipment needed to support all aspects of their peri-
operative care. Such infrastructure is not cost-effectively
maintained in low-volume centers.
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Conclusion
The inflammatory and physiologic changes associated
with obesity can result in myriad medical conditions
including hypertension, dyslipidemia, T2DM, CAD,
stroke, osteoarthritis, OSA, and certain forms of cancers
(Table 4). Anesthesiologists can optimize the likelihood
of a good outcome by identifying and intervening on fac-
tors that might increase the risk of perioperative compli-
cations. A thorough medical history to estimate a
patient’s functional status along with the cardiac risk as-
sociated with the planned procedure should guide pre-
operative cardiac testing to decrease postoperative
MACE. A comprehensive approach to OSA to include
routine screening may decrease postoperative respiratory
complications. Preoperative management of glucose aim-
ing for Hgb A1c of less than 6.5 % can decrease postoper-
ative surgical complications such as wound infections and
leaks. Equally important in the preoperative preparation is
the optimization of the patient’s nutritional status and psy-
chological wellbeing. While some data show that we can
potentially modify the risk of perioperative complications
in the obese patient, much work remains to be done.
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